CBG Faculty
Hossein Jadvar
Contact
U.S. Nuclear Regulatory Commission: Advisory Board Member on Medical Uses of Isotopes, 2020-2024
Western Regional Society of Nuclear Medicine: Distinguished Service Award, 2020
Los Angeles Magazine: Top Doctor (Diagnostic Radiology & Nuclear Medicine), 2020
Society of Nuclear Medicine and Molecular Imaging (SNMMI): Peter E. Valk MD Memorial Award, 2019
American College of Nuclear Medicine (ACNM): Best Mentor Award, 2018
University of Southern California: Best Mentor Award (Faculty-to-Faculty), 2017
World Association of Radiopharmacutical and Molecular Therapy (WARMTH): Prof. Ajit Padhy Memorial Oration Award, 2016
Journal of Nuclear Medicine (Supplement on Prostate Cancer): Invited Guest Editor, 2016
Society of Nuclear Medicine and Molecular Imaging (SNMMI): Fellow, 2016
Academy of Radiology Research: Distinguished Investigator Award, 2014
: Best Doctors in America, 2013-2020
: Best Doctors in America, 2013
Pasadena Magazine: San Gabriel Valley Top Doctors, 2010-2013
Western Regional Society of Nuclear Medicine: Distinguished Scientist Award, 2010
35th Annual Western Regional Society of Nuclear Medicine: Distinguished Scientist Award, 2010
PET Clinics and Theranostics (Prostate Cancer): Invited Guest Editor, 2009
National Institutes of Health: Charter Member, Medical Imaging Study Section, 2007-2011
USC Center for Excellence in Research: Inaugural Faculty Fellow, 2007-2010
IEEE-Engineering in Medicine and Biology Society: Senior Member, 2006
American College of Nuclear Medicine (ACNM): Fellow, 2003
Society of Nuclear Medicine: Marc Tetalman Young Investigator Award, 2000
American College of Nuclear Physicians (ACNP): Resident Research Award, 1998
Radiological Society of North America: Roentgen Resident/Fellow Research Award, 1997
National Institutes of Health: NIH Resident Research Award, 1994
NIH: NIH Resident Research Award, 1994
PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern California J Cancer Res Clin Oncol. 2020 Nov 18. . View in PubMed
Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline J Clin Oncol. 2020 Jun 10; 38(17):1963-1996. . View in PubMed
A review of prostate cancer imaging, positron emission tomography, and radiopharmaceutical-based therapy Can Urol Assoc J. 2020 Apr; 14(4):130-138. . View in PubMed
Invited Commentary: Nuclear Theranostics-The Path Forward Radiographics. 2020 10; 40(6):1741-1742. . View in PubMed
Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary Treatment J Nucl Med. 2020 04; 61(4):552-562. . View in PubMed
Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 10, RECIST 1. 1, and PSA response criteria. Theranostics. 2020; 10(7):3254-3262. . View in PubMed
Preclinical evaluation of a 64Cu-labeled disintegrin for PET imaging of prostate cancer Amino Acids. 2019 Nov; 51(10-12):1569-1575. . View in PubMed
18F-Fluciclovine PET/CT Detection of Recurrent Prostate Carcinoma in Patients With Serum PSA = 1 ng/mL After Definitive Primary Treatment Clin Nucl Med. 2019 Mar; 44(3):e128-e132. . View in PubMed
Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer with 18F-FDG PET/CT J Nucl Med. 2019 11; 60(11):1524-1530. . View in PubMed
18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial Lancet Oncol. 2019 09; 20(9):1286-1294. . View in PubMed
Gallium-68-Labeled Prostate-Specific Membrane Antigen-11 PET/CT of Prostate and Nonprostate Cancers AJR Am J Roentgenol. 2019 08; 213(2):286-299. . View in PubMed
Editorial Comment J Urol. 2019 08; 202(2):420-421. . View in PubMed
Management of Primary Osseous Spinal Tumors with PET PET Clin. 2019 Jan; 14(1):91-101. . View in PubMed
18F-NaF/223RaCl2 theranostics in metastatic prostate cancer: treatment response assessment and prediction of outcome Br J Radiol. 2018 Nov; 91(1091):20170948. . View in PubMed
Applications of PET/CT and PET/MR Imaging in Primary Bone Malignancies PET Clin. 2018 Oct; 13(4):623-634. . View in PubMed
PET in the Diagnostic Management of Soft Tissue Sarcomas of Musculoskeletal Origin PET Clin. 2018 Oct; 13(4):609-621. . View in PubMed
Incidental Detection of Meningioma by 18F-FMAU PET/CT in a Patient With Suspected Prostate Cancer Clin Nucl Med. 2018 Jul; 43(7):e245-e246. . View in PubMed
Diagnostic Performance of 18F-Fluciclovine in Detection of Prostate Cancer Bone Metastases Clin Nucl Med. 2018 Jul; 43(7):e226-e231. . View in PubMed
Clinical Nononcologic Applications of PET/CT and PET/MRI in Musculoskeletal, Orthopedic, and Rheumatologic Imaging AJR Am J Roentgenol. 2018 Jun; 210(6):W245-W263. . View in PubMed
Oligometastatic Prostate Cancer: Molecular Imaging and Clinical Management Implications in the Era of Precision Oncology J Nucl Med. 2018 09; 59(9):1338-1339. . View in PubMed
Point: The Existential Threat to Nuclear Medicine J Am Coll Radiol. 2018 03; 15(3 Pt A):384-386. . View in PubMed
Non-oncologic Applications of PET/CT and PET/MR in Musculoskeletal, Orthopedic, and Rheumatologic Imaging: General Considerations, Techniques, and Radiopharmaceuticals J Nucl Med Technol. 2017 Nov 10. . View in PubMed
Highlights of articles published in annals of nuclear medicine 2016 Eur J Nucl Med Mol Imaging. 2017 Oct; 44(11):1928-1933. . View in PubMed
Multimodal Imaging in Focal Therapy Planning and Assessment in Primary Prostate Cancer Clin Transl Imaging. 2017 Jun; 5(3):199-208. . View in PubMed
Appropriate Use Criteria for 18F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease J Nucl Med. 2017 12; 58(12):2026-2037. . View in PubMed
Future cancer research priorities in the USA: a Lancet Oncology Commission Lancet Oncol. 2017 11; 18(11):e653-e706. . View in PubMed
ACR and SNMMI Joint Credentialing Statement for PET/MRI of the Body J Nucl Med. 2017 07; 58(7):1174-1176. . View in PubMed
Effect of Androgen on Normal Biodistribution of [18F]-2'-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (18F-FMAU) in Athymic Non-tumor-bearing Male Mice Anticancer Res. 2017 02; 37(2):475-479. . View in PubMed
Duplex Doppler sonography: is there clinical relevance to elevated renal vein velocity in kidney transplants? Clin Imaging. 2016 Nov - Dec; 40(6):1237-1245.. View in PubMed
PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer J Nucl Med. 2016 Oct; 57(Suppl 3):25S-29S. . View in PubMed
Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer J Nucl Med. 2016 Oct; 57(Suppl 3):19S-24S. . View in PubMed
Is There Use for FDG-PET in Prostate Cancer? Semin Nucl Med. 2016 11; 46(6):502-506.. View in PubMed
Pathways to the Future of Nuclear Medicine Task Force: Phase 1 Report J Nucl Med. 2016 09; 57(9):17N-9N. . View in PubMed
Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer Abdom Radiol (NY). 2016 05; 41(5):889-98. . View in PubMed
Positron Emission Tomography in Prostate Cancer: Summary of Systematic Reviews and Meta-Analysis Tomography. 2015 Sep; 1(1):18-22. . View in PubMed
One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer Cancer Biother Radiopharm. 2015 Jun; 30(5):195-9. . View in PubMed
American College of Radiology and Society of Nuclear Medicine and Molecular Imaging Joint Credentialing Statement for PET/MR Imaging: Brain J Nucl Med. 2015 Apr; 56(4):642-5. . View in PubMed
Association of overall survival with glycolytic activity of castrate-resistant prostate cancer metastases Radiology. 2015 Feb; 274(2):624-5. . View in PubMed
Imaging Cellular Proliferation in Prostate Cancer with Positron Emission Tomography Asia Ocean J Nucl Med Biol. 2015; 3(2):72-6. . View in PubMed
Competitive advantage of PET/MRI Eur J Radiol. 2014 Jan; 83(1):84-94. . View in PubMed
Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature Am J Nucl Med Mol Imaging. 2014; 4(6):580-601. . View in PubMed
Molecular imaging of prostate cancer with PET J Nucl Med. 2013 Oct; 54(10):1685-8. . View in PubMed
Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer J Nucl Med. 2013 Aug; 54(8):1195-201. . View in PubMed
Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations Eur J Nucl Med Mol Imaging. 2013 Jul; 40 Suppl 1:S5-10. . View in PubMed
FDG-PET/MRI fusion demonstrating cricoarytenoid muscle hypermetabolism due to contralateral true vocal cord paralysis Rev Esp Med Nucl Imagen Mol. 2012 Nov-Dec; 31(6):362-3. . View in PubMed
[18F]-2'-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (18F-FMAU) in prostate cancer: initial preclinical observations Mol Imaging. 2012 Sep-Oct; 11(5):426-32. . View in PubMed
PET/CT in prostate cancer: non-choline radiopharmaceuticals Q J Nucl Med Mol Imaging. 2012 Aug; 56(4):367-74. . View in PubMed
Molecular imaging of prostate cancer: PET radiotracers AJR Am J Roentgenol. 2012 Aug; 199(2):278-91. . View in PubMed
Hepatocellular carcinoma and gastroenteropancreatic neuroendocrine tumors: potential role of other positron emission tomography radiotracers Semin Nucl Med. 2012 Jul; 42(4):247-54. . View in PubMed
Multimodality imaging in biochemical recurrence of prostate cancer: utility of (18)F-NaF PET/CT in early detection of metastasis Rev Esp Med Nucl Imagen Mol. 2012 Jul-Aug; 31(4):231-2. . View in PubMed
Can Choline PET Tackle the Challenge of Imaging Prostate Cancer? Theranostics. 2012; 2(3):331-2.. View in PubMed
FDG PET/CT demonstration of pancreatic metastasis from prostate cancer Clin Nucl Med. 2011 Oct; 36(10):961-2. . View in PubMed
Colonic FDG uptake pattern in subjects receiving oral contrast with no known or suspected colonic disease Clin Nucl Med. 2011 Sep; 36(9):754-6. . View in PubMed
ACR-ASTRO practice guideline for the performance of therapy with unsealed radiopharmaceutical sources Clin Nucl Med. 2011 Aug; 36(8):e72-80. . View in PubMed
Modeling and percept of transcorneal electrical stimulation in humans IEEE Trans Biomed Eng. 2011 Jul; 58(7):1932-9. . View in PubMed
Evolving cardiac conduction phenotypes in developing zebrafish larvae: implications to drug sensitivity Zebrafish. 2010 Dec; 7(4):325-31. . View in PubMed
Influence of trigger PSA and PSA kinetics on (11)C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy J Nucl Med. 2010 Mar; 51(3):498-9; author reply 499-500. . View in PubMed
18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization J Nucl Med. 2009 Nov; 50(11):1820-7. . View in PubMed
Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET Nat Rev Urol. 2009 Jun; 6(6):317-23. . View in PubMed
FDG PET in Prostate Cancer PET Clin. 2009 Apr 01; 4(2):155-61. . View in PubMed
Preface PET Clin. 2009 Apr; 4(2):ix. . View in PubMed
Molecular imaging of prostate cancer: a concise synopsis Mol Imaging. 2009 Mar-Apr; 8(2):56-64. . View in PubMed
Evaluation by 18F-FDG-PET of patients with anal squamous cell carcinoma Hell J Nucl Med. 2009 Jan-Apr; 12(1):26-9. . View in PubMed
[F-18]-fluorodeoxyglucose PET-CT of the normal prostate gland Ann Nucl Med. 2008 Nov; 22(9):787-93. . View in PubMed
Choline autoradiography of human prostate cancer xenograft: effect of castration Mol Imaging. 2008 May-Jun; 7(3):147-52. . View in PubMed
A systematic review on diagnostic accuracy of CT-based detection of significant coronary artery disease Eur J Radiol. 2008 Mar; 65(3):449-61. . View in PubMed
[F-18]-Fluorodeoxyglucose PET and PET-CT in diagnostic imaging evaluation of locally recurrent and metastatic bladder transitional cell carcinoma Int J Clin Oncol. 2008 Feb; 13(1):42-7. . View in PubMed
PET and PET/CT in pediatric oncology Semin Nucl Med. 2007 Sep; 37(5):316-31. . View in PubMed
[F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma J Comput Assist Tomogr. 2007 Mar-Apr; 31(2):223-8. . View in PubMed
Adenocarcinoma in an Indiana pouch on PET-CT Clin Nucl Med. 2007 Jan; 32(1):57-8. . View in PubMed
Actinomycosis mimicking anastomotic recurrent esophageal cancer on PET-CT Clin Nucl Med. 2006 Oct; 31(10):646-7. . View in PubMed
2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography/computed tomography imaging evaluation of esophageal cancer Mol Imaging Biol. 2006 May-Jun; 8(3):193-200. . View in PubMed
FDG PET-CT demonstration of Sjogren's sialoadenitis Clin Nucl Med. 2005 Oct; 30(10):698-9. . View in PubMed
Glucose metabolism of human prostate cancer mouse xenografts Mol Imaging. 2005 Apr-Jun; 4(2):91-7. . View in PubMed
PET in pediatric diseases Radiol Clin North Am. 2005 Jan; 43(1):135-52. . View in PubMed
Musculoskeletal system Semin Nucl Med. 2004 Oct; 34(4):254-61. . View in PubMed
Fusion positron emission tomography-computed tomography demonstration of epidural metastases Clin Nucl Med. 2004 Jan; 29(1):39-40. . View in PubMed
Electrocardiographic characterization of embryonic zebrafish Conf Proc IEEE Eng Med Biol Soc. 2004; 2004:3615-7. . View in PubMed
Diagnostic role of [F-18]-FDG positron emission tomography in restaging renal cell carcinoma Clin Nephrol. 2003 Dec; 60(6):395-400. . View in PubMed
FDG PET in suspected recurrent and metastatic prostate cancer Oncol Rep. 2003 Sep-Oct; 10(5):1485-8. . View in PubMed
Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography Clin Radiol. 2003 Mar; 58(3):215-21. . View in PubMed
Diagnostic utility of FDG PET in multiple myeloma Skeletal Radiol. 2002 Dec; 31(12):690-4. . View in PubMed
Incidental colonic fluorodeoxyglucose uptake: correlation with colonoscopic and histopathologic findings Radiology. 2002 Sep; 224(3):783-7. . View in PubMed
Pharmacologic interventions in nuclear radiology: indications, imaging protocols, and clinical results Radiographics. 2002 May-Jun; 22(3):477-90. . View in PubMed
Evaluation of pancreatic carcinoma with FDG PET Abdom Imaging. 2001 May-Jun; 26(3):254-9. . View in PubMed
Non-visualization of sentinel lymph node in patients with breast cancer Nucl Med Commun. 2001 Jan; 22(1):25-32. . View in PubMed
Comparison of fluorine-18 deoxyglucose and O-15 water PET in temporal lobe epilepsy Acta Neurol Belg. 2000 Dec; 100(4):214-20. . View in PubMed
Medical imaging in microgravity Aviat Space Environ Med. 2000 Jun; 71(6):640-6. . View in PubMed
Effect of atropine and sincalide on the intestinal uptake of F-18 fluorodeoxyglucose Clin Nucl Med. 1999 Dec; 24(12):965-7. . View in PubMed
Physiologic Source of Intestinal FDG UptakeEffect of Atropine and Sincalide. Clin Positron Imaging. 1999 Nov; 2(6):318. . View in PubMed
Evaluation of Rare Tumors with [F-18]Fluorodeoxyglucose Positron Emission Tomography Clin Positron Imaging. 1999 May; 2(3):153-158. . View in PubMed
Annular pancreas in adults: imaging features in seven patients Abdom Imaging. 1999 Mar-Apr; 24(2):174-7. . View in PubMed
Evaluation of suspected recurrent papillary thyroid carcinoma with [18F]fluorodeoxyglucose positron emission tomography Nucl Med Commun. 1998 Jun; 19(6):547-54. . View in PubMed
Effect of radionuclide renograms on treatment of patients with spinal cord injuries AJR Am J Roentgenol. 1997 Oct; 169(4):1045-7. . View in PubMed
False-negative fluorine-18-FDG PET in metastatic carcinoid J Nucl Med. 1997 Sep; 38(9):1382-3. . View in PubMed
Computer analysis of the electrocardiogram during esophageal pacing cardiac stress IEEE Trans Biomed Eng. 1991 Nov; 38(11):1089-99. . View in PubMed
A reusable perfusion supporting tissue-mimicking material for ultrasound hyperthermia phantoms Med Phys. 1990 May-Jun; 17(3):380-90. . View in PubMed
A system for simultaneous esophageal atrial pacing and ventricular recording in computer analysis of posterior ischemia J Electrocardiol. 1989; 22 Suppl:248-52. . View in PubMed
Computer processing of the electrocardiogram during transesophageal atrial pacing-induced stress J Electrocardiol. 1987 Oct; 20 Suppl:106-7. . View in PubMed
Lead configurations in esophageal electrocardiography Med Instrum. 1987 Jun; 21(3):158-65. . View in PubMed
Associate Professor of Radiology (Tenure)
Associate Professor of Urology
Associate Professor of Biomedical Engineering
University of Southern California, Los Angeles, CA, USA
Past President, American College of Nuclear Medicine (ACNM)
Past President, Society of Nuclear Medicine and Molecular Imaging (SNMMI)
Nuclear Medicine Physician Representative, Advisory Committee on Medical Uses of Isotopes (ACMUI), U.S. Nuclear Regulatory Commission (NRC)
Dr. Jadvar is currently a tenured Associate Professor of Radiology in the Keck School of Medicine, at the University of Southern California (USC), Los Angeles, California, USA. He has a joint appointment as Associate Professor of Urology and is a member of the USC Norris Comprehensive Cancer Center, and Associate Professor of Biomedical Engineering in the USC Viterbi School of Engineering. He is the past president and fellow of both the American College of Nuclear Medicine (ACNM) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
Dr. Jadvar received the BS degree in chemical engineering from Iowa State University, Ames (1982), MS in biomedical engineering from University of Wisconsin, Madison (1984), MS in computer engineering (1986) and PhD in bioengineering (1988), both from the University of Michigan, Ann Arbor, the MD degree from the University of Chicago Pritzker School of Medicine (1993), Master’s in Public Health (MPH) degree from Harvard University (2005), and the Executive Master’s in Business Administration (MBA) from USC Marshall Scholl of Business (2007). He was an intern in internal medicine at the University of California San Francisco (UCSF) during 1993-94, a diagnostic radiology and nuclear medicine resident at Stanford University, during 1994-98, and a clinical fellow in positron emission tomography (PET) with the Harvard Medical School Joint Program in Nuclear Medicine, during 1998-99. He has completed executive educational certificate programs in clinical effectiveness at Harvard Medical School, and in leadership at University of Pennsylvania (Wharton).
He was a Visiting Associate Scientist in Bioengineering at the California Institute of Technology (Caltech) during 2001-06. Dr. Jadvar is on the leadership editorial boards of Journal of Nuclear Medicine, European Journal of Nuclear Medicine and Molecular Imaging (Associate Editor), Radiology (Consultant to the Editor), and Clinical Nuclear Medicine (Deputy Editor), and is member of the editorial boards of many other peer-reviewed journals. He is the past recipient of the SNMMI Mark Tetalman Young Investigator Award, the Western Regional SNMMI Distinguished Scientist Award and Distinguished Service Award, the Academy of Radiology and Biomedical Imaging Research Distinguished Investigator Award, the inaugural fellowship in the USC Center for Excellence in Research, the inaugural Prof. Ajit Padhy Award from the World Association of Radiopharmaceutical and Molecular Therapy (WARMTH), the SNMMI PET Center of Excellence Peter E. Valk Memorial Award, and the Best Mentor Awards from both USC and the ACNM. Dr. Jadvar serves as the nuclear medicine physician representative on the Advisory Committee on Medical Uses of Isotopes (ACMUI) of the U.S. Nuclear Regulatory Commission (NRC).
He has been a National Institutes of Health (NIH) funded investigator and serves on multiple NIH review panels (with one term as a chartered member for MEDI study section), as well as the Department of Defense (DOD) Congressionally Directed Medical Research Programs-Prostate Cancer Research Program and the Imaging Technology and Informatics Review Panel of the Cancer Prevention Research Institute of Texas (CPRIT). He has written more than 150 peer-reviewed journal articles, published 4 books, 39 book chapters, 9 U.S. and European patents, numerous conference abstracts and full articles, and has had more than 200 invited speaker presentations and visiting professorships at national and international venues. His research interests include applications of PET in clinical outcome research and in translational molecular imaging research with particular current interest in prostate cancer, theranostics, and targeted radionuclide therapy.
